Sugi Predict

Sugi Predict / Compounds / SCHEMBL28392

SCHEMBL28392

SCHEMBL28392

CC(C)(C)OC(=O)N1CC(C#N)C1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.50
▸ USP2 O75604 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ MEN1 O00255 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ HPGD P15428 1/20 0.45
▸ CTSK P43235 1/20 0.44
▸ RECQL P46063 1/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ DPP4 P27487 1/20 0.42
▸ GPR119 Q8TDV5 4/20 0.42
▸ EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13820 0.86 MAPT (0.53) USP2SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL12323775 0.86 NR1H2 (0.60) NR1H2USP2SMN1; SMN2MEN1ALDH1A1
SCHEMBL20936862 0.86 NR1H2 (0.60) NR1H2USP2SMN1; SMN2MEN1ALDH1A1
SCHEMBL56905 0.86 MAPT (0.53) USP2SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL1968766 0.86 MAPT (0.53) USP2SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL29501520 0.86 NR1H2 (0.60) NR1H2USP2SMN1; SMN2MEN1ALDH1A1
SCHEMBL18703559 0.86 NR1H2 (0.60) NR1H2USP2SMN1; SMN2MEN1ALDH1A1
SCHEMBL4221580 0.84 MEN1 (0.61) USP2SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL1970337 0.84 MEN1 (0.61) USP2SMN1; SMN2MEN1ALDH1A1MAPT
SCHEMBL1970335 0.84 MEN1 (0.61) USP2SMN1; SMN2MEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 327 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090330-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
US-20260042771-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN ASTELLAS PHARMA INC. (JP) 2026-02-12 — — US disclosed
EP-4688791-A1 TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2026-02-11 — — EP disclosed
EP-4680609-A1 KRAS MODULATORS AND USES THEREOF Quanta Therapeutics, Inc. (US) 2026-01-21 — — EP disclosed
US-12522593-B2 Azacycloalkyl carbonyl cyclic amine compound ALIVEXIS, INC. (JP) 2026-01-13 — — US disclosed
US-20260008789-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS INC (US) 2026-01-08 — — US disclosed
US-20250368666-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES INC (US) 2025-12-04 — — US disclosed
US-12479820-B2 Pyridin-3-yl derivatives IDORSIA PHARMACEUTICALS LTD (CH) 2025-11-25 — — US disclosed
US-20250313556-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS RETUNE PHARMA, INC. 2025-10-09 — — US disclosed
US-12421254-B2 KRAS modulators and uses thereof QUANTA THERAPEUTICS, INC. (US) 2025-09-23 — — US disclosed
WO-2006067529-A1 PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS MERCK SHARP & DOHME LIMITED (GB) 2006-06-29 — — WO disclosed
WO-2006014918-A2 HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK & CO., INC. (US) 2006-02-09 — — WO disclosed
WO-2005110983-A1 AZETIDINE GLYCINE TRANSPORTER INHIBITORS MERCK & CO., INC. (US) 2005-11-24 — — WO disclosed
US-6140347-A Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists MERCK SHARP & DOHME LTD. (GB) 2000-10-31 — — US disclosed
US-5854268-A Azetidine, pyrrolidine and piperidine derivatives MERCK SHARP & DOHME, LTD. (GB) 1998-12-29 — — US disclosed
WO-1997042189-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS MERCK SHARP & DOHME LIMITED (GB) 1997-11-13 — — WO disclosed
EP-0394991-B1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO (JP) 1994-08-17 — — EP disclosed
US-5102877-A Carbapenicillin antibiotics FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-04-07 — — US disclosed
WO-1992002521-A1 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-02-20 — — WO disclosed
EP-0394991-A1 1-Azabicyclo(3.2.0)Hept-2-Ene-2-carboxylic acid compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042771-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN KRAS, NRAS, HRAS NR1H2 221/4885USP2 2904/4885SMN1; SMN2 1450/4885
US-20260008789-A1 KRAS MODULATORS AND USES THEREOF KRAS, NRAS, HRAS NR1H2 674/4885USP2 2178/4885SMN1; SMN2 545/4885
US-12421254-B2 KRAS modulators and uses thereof KRAS, NRAS, HRAS NR1H2 2308/4885USP2 2168/4885SMN1; SMN2 2853/4885
US-20250368666-A1 INDAZOLE COMPOUNDS FGFR1, FGFR3, FGFR2 NR1H2 473/4885USP2 3629/4885SMN1; SMN2 2326/4885
US-20250313556-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS KIT, PRKCH, PRKCB NR1H2 2976/4885USP2 1747/4885SMN1; SMN2 4366/4885
US-12479820-B2 Pyridin-3-yl derivatives LPAR1, LPAR3, LPAR2 NR1H2 241/4885USP2 4740/4885SMN1; SMN2 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.